Go Deep
Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 18,836 | -4.6 | 4.07 | 0.33 | 1,457.08 |
| Oct 2026 | 18,918 | -4.6 | 4.00 | 0.33 | 1,428.01 |
| Oct 2026 | 18,839 | -4.7 | 4.07 | 0.33 | 1,451.95 |
| Oct 2026 | 19,168 | -4.3 | 3.79 | 0.33 | 1,349.69 |
| Oct 2026 | 18,858 | -4.6 | 4.05 | 0.33 | 1,444.05 |
| Oct 2026 | 18,529 | -4.9 | 4.33 | 0.33 | 1,542.66 |
| Oct 2026 | 18,593 | -4.9 | 4.27 | 0.33 | 1,519.94 |
| Oct 2026 | 18,687 | -4.8 | 4.19 | 0.33 | 1,488.54 |
| Oct 2026 | 18,735 | -4.7 | 4.15 | 0.33 | 1,480.50 |
Dyne Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -178,556,000.0 | -120,854,000.0 | -111,955,000.0 | -108,041,000.0 |
| EPS | -1.1 | -0.7 | -0.8 | -0.8 |
Dyne Therapeutics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Profit | -446,214,000.0 | -317,418,000.0 | -235,937,000.0 | -168,099,000.0 | — |
| EPS | -3.5 | -3.4 | -4.0 | -3.2 | — |
Dyne Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 1,186,958,000.0 | 691,234,000.0 | 165,082,000.0 | 306,325,000.0 | — |
| Total Liabilities | 214,829,000.0 | 61,396,000.0 | 73,790,000.0 | 53,961,000.0 | — |
| Total Equity | 972,129,000.0 | 629,838,000.0 | 91,292,000.0 | 252,364,000.0 | — |
Owes vs Owns
Dyne Therapeutics, Inc. owed $0.29 for every $1 it owned in Jun 2026, up from $0.18 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.29× | 0.18× | 0.09× | 0.45× | 0.18× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Dyne Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 93.6%Fixed assets (tangible) 3.8%Other assets 2.7%
How it's funded — Dec 2025
Long-term debt 12.5%Payables 0.7%Other liabilities 4.5%Shareholders' equity 81.9%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 1,110.6 | 642.3 | 123.1 | 256.0 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 44.8 | 30.0 | 33.4 | 38.4 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 31.6 | 19.0 | 8.6 | 11.9 |
| Liabilities & equity | ||||
| Short-term debt | 5.0 | 4.8 | 4.7 | 4.6 |
| Long-term debt | 148.9 | 19.1 | 22.7 | 25.9 |
| Payables | 8.1 | 6.6 | 22.9 | 5.3 |
| Other liabilities | 52.8 | 30.8 | 23.4 | 18.2 |
| Shareholders' equity | 972.1 | 629.8 | 91.3 | 252.4 |
| Net tangible assets | 972.1 | 629.8 | 91.3 | 252.4 |
Dyne Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -403,207,000.0 | -292,369,000.0 | -188,158,000.0 | -153,645,000.0 | — |
| Investing Activities | -28,751,000.0 | -204,076,000.0 | 83,311,000.0 | 87,202,000.0 | — |
| Financing Activities | 890,307,000.0 | 809,895,000.0 | 54,322,000.0 | 37,390,000.0 | — |